Matisse Secures EU Funding for Sepsis Breakthrough

Matisse Pharmaceuticals, a clinical stage company, and EpiDisease, a biotechnology firm focused on epigenetics, have secured a Eurostars grant of €524,000 for their collaborative eHISTOCURE project. This initiative aims to enhance the treatment and diagnosis of sepsis, a leading cause of death in ICUs worldwide. The project focuses on the development and validation of Matisse’s M6229 therapy and the HistSHOCK IVD kit, with the latter serving as a Companion Diagnostic tool. This precision medicine approach is designed to tackle the high sepsis mortality rates by targeting inflammation through M6229, a therapy that neutralizes cytotoxic histones. EpiDisease’s HistSHOCK CDx tool, based on mass spectrometry, enables the identification of patients most likely to benefit from M6229, potentially expediting market approval. The collaboration promises significant cost and capacity benefits for ICUs and improved patient quality of life post-discharge.